Liver Transplant Tolerance Induction via Anti-CD2 Antibody
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immunosuppressive regimens for liver transplantation are associated with chronic rejection and significant side effects, necessitating the development of tolerance induction methods to avoid destructive immune responses and reduce reliance on systemic immunosuppression.
Innovation Solution
Administration of an anti-CD2 antibody, such as siplizumab, in combination with cyclophosphamide and calcineurin inhibitors, to modulate the immune response and induce tolerance in liver transplant recipients, potentially allowing for the reduction or elimination of long-term immunosuppressive therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic immunosuppression is used to prevent rejection, then graft survival is improved, but patient health is worsened due to side effects and comorbidities
Solution Approach 1:
The patent extracts the harmful aspect of immunosuppression by removing the need for continuous systemic immunosuppressive therapy while maintaining graft protection through tolerance induction. The method separates the protective function (rejection prevention) from the harmful function (systemic immunosuppression side effects), achieving graft survival without the associated comorbidities.
Solution Approach 2:
The patent converts the harmful chronic immune response into a beneficial tolerant state. By inducing regulatory T-cell mediated tolerance, the immune system's protective function is harnessed to accept the graft without causing damage, transforming the potentially harmful rejection response into a beneficial acceptance state that eliminates the need for harmful immunosuppressive drugs.
2Object-generated harmful factors
If tolerance induction is achieved, then immunosuppression is reduced or eliminated, but the complexity of the induction process increases
Solution Approach 1:
The patent applies preliminary action by administering induction agents (such as anti-CD2 antibodies, cyclophosphamide, or other tolerance-inducing medications) at the time of transplantation to establish regulatory T-cell mediated tolerance before the patient is exposed to long-term immunosuppression. This preliminary tolerance induction simplifies long-term management by preventing rejection mechanisms before they become established.
3Ease of operation
If early immunosuppression withdrawal is attempted, then patient quality of life is improved, but rejection risk increases
Solution Approach 1:
The patent uses preliminary action by establishing tolerance through regulatory T-cell induction at the time of transplant before attempting immunosuppression withdrawal. This preliminary tolerance foundation allows for earlier and safer withdrawal of immunosuppressive therapy while maintaining graft protection, as the tolerance mechanism is already in place to prevent rejection.
Solution Approach 2:
The patent implements feedback by continuously monitoring patient responses, graft function, and immune status to guide the timing and extent of immunosuppression withdrawal. This feedback mechanism ensures that withdrawal occurs only when tolerance is sufficiently established, balancing quality of life improvement with rejection risk management.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach aims to achieve stable allograft function without ongoing immunosuppression, reducing chronic rejection and side effects, and improving long-term outcomes for liver transplant patients by modulating the immune response and promoting tolerance.
Implementation Method 1
Administration of an anti-CD2 antibody, such as siplizumab, in combination with cyclophosphamide and calcineurin inhibitors, to modulate the immune response and induce tolerance in liver transplant recipients
Implementation Method 2
Administration of an anti-CD2 antibody, such as siplizumab, in combination with cyclophosphamide and calcineurin inhibitors, to modulate the immune response and induce tolerance in liver transplant recipients
Data Source
AI summary
Provided herein are methods for inducing tolerance to an organ (e.g., liver) transplant in a patient. Compositions for use with these methods and kits are also disclosed.